Publications
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia2020 | Central Library of Charles University
- Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia2019 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Treatment of repeatedly relapsing chronic lymphocytic leukemia2018 | Faculty of Medicine in Hradec Králové
- Treatment of elderly and comorbid patients with chronic lymphocytic leukemia2017 | Faculty of Medicine in Hradec Králové
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Practical approach to management of chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia2012 | Faculty of Medicine in Hradec Králové
- Report of University Hospital Hradec Králové to the clinical trial protocol No: GO28667Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. GO28667Publication without faculty affiliation
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
Loading network view...